Related Experiment Video
Updated: Apr 27, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.0K
Delirium diagnosis, screening and management
Peter G Lawlor1, Shirley H Bush
1aDepartment of Medicine Epidemiology and Community Medicine, Division of Palliative Care, University of Ottawa bThe Ottawa Hospital Research Institute cBruyère Research Institute dBruyère Continuing Care eDepartment of Medicine, Division of Palliative Care, University of Ottawa, Ottawa, Ontario, Canada.
Current Opinion in Supportive and Palliative Care
|July 9, 2014
Summary
Systematic delirium screening is recommended for palliative care patients. Further research is needed to evaluate clinical outcomes and develop management guidelines for delirium in this population.
Area of Science:
- Geriatrics
- Palliative Care
- Psychiatry
Background:
- Delirium diagnosis, screening, and management are critical in various clinical settings.
- Palliative and supportive care present unique challenges for delirium management.
- Recent updates to diagnostic criteria and screening tools are available.
Purpose of the Study:
- To review recent developments in delirium diagnosis, screening, and management.
- To inform delirium care within palliative and supportive settings.
- To highlight the need for evidence-based guidelines in this population.
Main Methods:
- Literature review of recent developments in delirium care.
- Analysis of updated diagnostic criteria (DSM-5).
- Evaluation of screening tools and management guidelines.
Main Results:
- Updated delirium diagnostic criteria in DSM-5.
- Poor recognition linked to clinical features, communication, and lack of screening.
- Validated cognitive and observational screening tools are available.
- Guidelines for intensive care may inform other settings.
- Modified Richmond Agitation-Sedation Scale validated for palliative care.
Conclusions:
- Systematic delirium screening is advocated for palliative care but requires outcome evaluation.
- Clinical outcomes, including patient comfort, need critical assessment.
- Randomized controlled trials are essential for developing management guidelines in palliative care.
Related Concept Videos
01:30Dementia
685
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
685
01:22Dementia l: Introduction
29
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
29
01:29Alzheimer Disease l: Introduction
19
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
19
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:27Diagnostic and Statistical Manual of Mental Disorders (DSM)
2.0K
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
2.0K